Table: Personalized Cancer Vaccine Trials in the United States
Table: Personalized Cancer Vaccine Trials in the United States

Table: Personalized Cancer Vaccine Trials in the United States

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.

Jul 15, 2019
Jasreet Hundal, Elaine R. Mardis

ABOVE: © ISTOCK.COM, JURGAR

Research into personalized cancer vaccines is booming. Explore the ongoing clinical trials in the country in the list below.

Trial ID
 PhaseCancer typeInstitution/ Company SponsorsVaccine PlatformPatient StatusPatient Accrual Target
NCT03568058Phase 1Advanced cancersUniversity of California, San DiegoSynthetic long peptideRecruiting10
NCT03199040Phase 1Breast cancerWashington University School of Medicine, MedImmuneDNARecruiting24
NCT02348320Phase 1Breast cancerWashington University School of MedicineDNARecruiting30
NCT03121677Phase 1Follicular lymphomaWashington University School of Medicine, Bristol-Myers SquibbSynthetic long peptideRecruiting20
NCT03122106Phase 1Pancreatic cancerWashington University School of Medicine, National Cancer Institute (NCI)DNARecruiting15
NCT03532217Phase 1Prostate cancerWashington University School of Medicine, Bristol-Myers SquibbDNARecruiting20
NCT03598816Phase 2Renal cell carcinomaWashington University School of Medicine, MedImmuneDNANot yet recruiting48
NCT03068832Phase 1Pediatric brain tumorWashington University School of MedicineSynthetic long peptideNot yet recruiting10
NCT03422094Phase 1GlioblastomaWashington University School of Medicine, Bristol-Myers SquibbSynthetic long peptideRecruiting

30
NCT03289962Phase 1Multiple solid cancersGenentech, Biontech RNA Pharmaceuticals GmbHRNARecruiting567
NCT03223103Phase 1GlioblastomaIcahn School of Medicine at Mount Sinai, NovoCureSynthetic long peptideRecruiting20
NCT02721043Phase 1Multiple solid tumorsIcahn School of Medicine at Mount SinaiSynthetic long peptideRecruiting20
NCT03359239Phase 1Urothelial/ bladder cancerIcahn School of Medicine at Mount Sinai, GenentechSynthetic long peptideRecruiting15
NCT03380871Phase 1Lung cancersNeon Therapeutics, Merck Sharp & Dohme Corp.Synthetic long peptideActive, not currently recruiting15
NCT03597282Phase 1Metastatic melanomaNeon Therapeutics, Apexigen, Inc.Synthetic long peptideRecruiting

40
NCT02897765Phase 1Melanoma, lung cancer, bladder cancerNeon Therapeutics, Bristol-Myers SquibbSynthetic long peptideActive, not currently recruiting55
NCT03633110Phase 1/2aMultiple solid cancersGenocea BiosciencesSynthetic long peptideRecruiting99
NCT03631043Phase 1Smoldering plasma cell myelomaMD Anderson Cancer Center, National Cancer InstituteSynthetic long peptideActive, not currently recruiting30
NCT02950766Phase 1Kidney cancerDana-Farber Cancer Institute, Bristol-Myers Squibb, OncovirSynthetic long peptideRecruiting15
NCT02287428Phase 1GlioblastomaDana-Farber Cancer Institute, The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme Corp.Synthetic long peptideActive, not currently recruiting46
NCT03361852Phase 1Follicular lymphomaDana-Farber Cancer InstituteSynthetic long peptideNot yet recruiting20
NCT03219450Phase 1Lymphocytic leukemiaDana-Farber Cancer Institute, Oncovir, Neon TherapeuticsSynthetic long peptideNot yet recruiting10
NCT03480152Phase 1/2Multiple solid cancersNational Cancer InstituteRNARecruiting64
NCT03092453Phase 1MelanomaUniversity of Pennsylvania
Dendritic Cell
Recruiting12
NCT03300843Phase 2Multiple solid cancersNational Cancer InstituteDendritic cellRecruiting86
NCT03639714Phase 1/2Multiple solid cancersGritstone Oncology, Bristol-Myers SquibbRNARecruiting214

Read the full story.